CURRENT SITUATION OF LIVER FUNCTION DUE TO TB TREATMENT DRUGS AT THAI NGUYEN PROVINCIAL LUNG HOSPITAL

Thị Hiếu Ngô , Hà Hoàng, Trường Giang Nguyễn

Main Article Content

Abstract

Objective: Describe the clinical and paraclinical characteristics of patients with liver damage caused by tuberculosis drugs at Thai Nguyen Provincial Lung Hospital in 2022-2023. Identify some factors related to patients with liver damage caused by tuberculosis drugs. Subjects: Patients treated for tuberculosis with regimens A1 and B1 from October 2022 to October 2023. Methods: Description; Purposive convenience sampling. The sample size obtained was 40 patients. Processing data according to medical statistics. Results: Study subjects had an average age of 49.93± 16.5 years. Male patients account for 65.0% and female patients account for 35.0%; Of which 27 patients were treated for pulmonary tuberculosis, 13 patients were treated for extrapulmonary tuberculosis. Patients with liver damage caused by anti-TB drugs included signs of fatigue (n = 33), loss of appetite (n = 18), fever (n = 14), and rash (n = 10). Clinical manifestations of anorexia and fever are more common in patients with level 3 - 4 liver damage than level 1 - 2 and the difference between groups is statistically significant (p < 0.05). Some factors that affect the severity of drug-induced liver damage include advanced age, history of alcohol consumption and primary liver disease, the difference is not statistically significant with p > 0.05. Conclusion: Research on 40 patients treated for tuberculosis at Thai Nguyen Provincial Lung Hospital showed mainly liver damage of level 1-2, common clinical manifestations of liver damage of level 3-4, some factors. For example, age, thin body condition, history of alcohol consumption and primary liver disease have a higher risk of liver damage caused by anti-tuberculosis drugs.

Article Details

References

1. Bộ Y tế (2020), Hướng dẫn chẩn đoán, điều trị và phòng bệnh lao, Quyết định 1314.
2. Lương Tiến Dũng, (2017), "Khảo sát độc tính trên gan của bệnh nhân khi dùng thuốc điều trị lao bằng phác đồ A1 tại Bệnh viện 71 Trung Ương", Luận văn chuyên khoa 1, trường Đại học Dược Hà Nội.
3. Phan Thị Đào Hạnh và Cs, (2019), nghiên cứu phản ứng có hại của thuốc lao điều trị nội trú tại bệnh viện Phổi Hà Tĩnh giai đoạn 11/2016 - 4/2019. Báo cáo ADR, sở Y tế Hà Tĩnh.
4. Lê Thị Luyến, (2020), Bệnh lao, Nhà xuất bản Đại học Quốc Gia Hà Nội.
5. Hong Zhao, Yangbing Wang, Ting Zhang, Qi Wang and Wen Xie, (2020), Drug-Induced Liver Injury from Anti-Tuberculosis Treatment: A Retrospective Cohort Study. Published online 2020 Mar 7. Prepublished online 2020 Jan 22. doi: 10. 12659/MSM.920350.
6. Anand AC, Seth AK, Paul M, Puri P. Rík factor of hepatotoxicity during anti-tuberculosis treatment. Med J Armed Forces India. 2006; 62: 45-49.
7. Globan Tuberculosis report 2022, Geneva: World Health Organnization, 2022.
8. Tweed CD, Wills GH, Crook AM & Cs. (2018) " Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study". Tweed et al BMC Med. 2018; 16:46
9. Shuting, Yanwan Shangguan & Cs, (2020), “ Rík factor for acute liver failure among inpatients with anti-tuberculosis drug-induced liver inju”, J Int Med Res. 2020 Jan;48(1): Epub 2018 Nov 26.